Phase 2 testing of SAR445877, an immune‑modulating treatment for NSCLC that progressed after immunotherapy

A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer

This will try the drug SAR445877 to see if it can control advanced non‑small cell lung cancer in people whose tumors progressed after prior immune checkpoint inhibitor therapy.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 29 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: M.D. Anderson Cancer Center (Academic / other)
• Drugs / interventions: chemotherapy, radiation, prednisone
• Locations: 1 site (Houston, Texas)
• Trial ID: NCT07133425 on ClinicalTrials.gov

What this trial studies

This is a phase 2 platform study giving SAR445877 to adults with locally advanced or metastatic non‑small cell lung cancer who have had disease progression after prior anti‑PD-(L)1 therapy. The main goals are to look for early signals of anti‑tumor activity and to collect tumor and blood biomarkers linked to the drug's mechanism and to response or resistance. Participants must have at least one lesion suitable for repeat biopsy so investigators can compare tissue before and after treatment, and safety and tumor responses will be monitored over time. The study is sponsored by M.D. Anderson Cancer Center in collaboration with Sanofi and is conducted at the MD Anderson site in Houston, Texas.

Who should consider this trial

Good fit: Adults (≥18 years) with histologically confirmed locally advanced or metastatic NSCLC that progressed after at least six weeks of anti‑PD-(L)1 therapy and who have a lesion suitable for repeat biopsy are ideal candidates.

Not a fit: Patients who have not received prior immune checkpoint inhibitors, who cannot safely undergo tumor biopsy, or who are too medically frail or rapidly declining are unlikely to benefit from this study.

Why it matters

Potential benefit: If successful, SAR445877 could slow tumor growth or prolong the time patients live without disease worsening after prior immunotherapy.

How similar studies have performed: Some other immunomodulatory approaches have produced occasional early signals in ICI‑refractory NSCLC but results have been mixed and no widely effective salvage immunotherapy has been established, so this approach remains relatively novel.

Eligibility criteria

Eligibility Criteria

1. Ability to understand and willingness to sign informed consent form (ICF) prior to initiation of the study and any study procedures.
2. Age ≥18 years. Because no dosing or adverse event data are currently available on the use of SAR445877 in participants \<18 years of age, children are excluded from this study.
3. Participants with histologically documented locally advanced or metastatic NSCLC who have had disease progression after treatment with all available therapies for metastatic disease that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment:
4. Prior immune checkpoint inhibitor (anti-PD-(L)1) exposure. Participants need to have received at least 6 weeks of exposure to anti-PD-(L)1 and developed disease progression. Treatment with neoadjuvant or adjuvant ICI is acceptable if participant developed progression within one year of start of ICI therapy.
5. One lesion suitable for repeat biopsy without significant risk to the participant.
6. Measurable disease per RECIST v1.1.
7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 .
8. Adequate organ and marrow function as defined below, obtained before study treatment initiation:

   1. Hemoglobin \>9.0 g/dL
   2. Absolute neutrophil count ≥1000/mcL
   3. Platelets ≥75,000/mcL
   4. Total bilirubin ≤1.5 institutional upper limit of normal (ULN). Documented Gilbert syndrome is allowed if total bilirubin is ≤3 × ULN.
   5. AST/ALT ≤2.5 × institutional ULN. Transaminases up to 5 × ULN in the presence of liver metastases.
   6. Measured or calculated creatinine clearance (CrCl; glomerular filtration rate can also be used in place of creatinine or CrCl) ≥30 mL/min (CrCl should be calculated per institutional standard).
   7. For participants not receiving therapeutic anticoagulation: international normalized ratio or activated partial thromboplastin time ≤1.5 × ULN. For participants receiving therapeutic anticoagulation: stable anticoagulant regimen.
9. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test result at screening.
10. WOCBP must agree to use highly effective contraception for the duration of study participation and for 60 days after completion of study treatment. A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a post-menopausal state (≥12 continuous months of amenorrhea with no identified cause other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and/or uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis). Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this study must also agree to use adequate contraception for the duration of study participation and for 60 days after completion of study treatment. In addition, male participants must be willing to refrain from sperm donation during this time.
11. Willing to undergo mandatory biopsies and blood collections as required by the study.
12. Participants with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression and participant is clinically stable without requirement of steroid treatment for ≥ 7 days prior to the first dose of study treatment.
13. Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.

Exclusion Criteria

1. History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drugs.
2. Participants who are pregnant or breastfeeding.
3. Participants with an active, known or suspected autoimmune disease. Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
4. Participants with a condition requiring systemic treatment with either corticosteroid (\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of study treatment initiation. Inhaled or topical steroids, and adrenal replacement steroid doses, are permitted in the absence of active autoimmune disease.
5. History of interstitial lung disease (ILD) or checkpoint inhibitor-induced pneumonitis.
6. Known history of positive test for human immunodeficiency virus or known acquired immunodeficiency syndrome.
7. Acute or chronic hepatitis B virus or hepatitis C virus infection. Prior viral exposure with cleared or fully treated infection based on negative HCV viral load is permitted.
8. Previous solid organ or allogeneic hematopoietic stem cell transplant.
9. Active infection requiring IV antibiotics or other uncontrolled intercurrent illness requiring hospitalization.
10. Significant cardiovascular/cerebrovascular disease, including stroke, myocardial infarction, or prolonged QTc (\> 480msec) within 3 months. Participants on beta blockers must be able to stop beta blockers for duration of their time on study treatment period when applicable.
11. Participants who have not recovered from AEs due to prior anticancer therapy (i.e., have residual toxicities \> Grade 1) with the exception of alopecia, hearing loss, grade 2 neuropathy or endocrinopathy managed with hormone replacement therapy.
12. Participants who have previously been treated with PD-1, PD-L1, or CTLA-4 inhibitors and required permanent discontinuation or systemic immunosuppression (e.g. immune inhibitory monoclonal antibodies) due to irAEs.
13. Participants who are receiving any other investigational agents.
14. Treatment with a live, attenuated vaccine within 4 weeks prior to study treatment initiation, or anticipation of need for such a vaccine during the course of the study or within 5 months after the last dose of study treatment. Non-live COVID vaccines will be allowed on study, but it is recommended to avoid their use during the first treatment cycle (from 3 days prior to Cycle 1 Day 1 through Cycle 2 Day 3).
15. Participants must have adequate washout from prior therapy at the time of study treatment initiation: 4 weeks from major surgery; 4 weeks from antibody-based therapy; 3 weeks from prior PD-(L)1 inhibitor exposure; 2 weeks or 5 half-lives (whichever is shorter) from any targeted therapy or small molecule therapy; 3 weeks or 5 half-lives (whichever is shorter) from chemotherapy or 6 weeks in the case of certain therapies (e.g., extensive radiotherapy, mitomycin C, and nitrosoureas); and 2 weeks from radiation therapy. Palliative radiotherapy is permitted for a preexisting lesion, provided it does not interfere with the assessment of tumor target lesions (e.g., the lesion to be irradiated must not be a site of measurable disease).
16. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, ductal carcinoma in situ, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer.
17. Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study.
18. Inability to comply with the study and follow-up procedures.

Where this trial is running

Houston, Texas

• MD Anderson Cancer Center — Houston, Texas, United States (Recruiting)

Study contacts

• Principal investigator: Natalie Vokes, MD — M.D. Anderson Cancer Center
• Study coordinator: Natalie Vokes, MD

Conditions Non-Small Cell Lung Cancer; ICI-refractory